Olaparib In Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03344965

Recruitment Status : Active, not recruiting

First Posted : November 17, 2017

Last Update Posted : February 20, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Johns Hopkins University

AstraZeneca

Dana-Farber Cancer Institute

Information provided by (Responsible Party):

Nadine Tung, Beth Israel Deaconess Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	July 30, 2024
Estimated Study Completion Date :	December 30, 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.

To Top